APA (7th ed.) Citation

S, N., T, M., K, M., K, Y., K, T., H, M., . . . Y, D. (2026). NY-ESO-1 and PD-L1 as biomarkers associated with nivolumab response and outcome in unresectable or recurrent esophageal squamous cell carcinoma: A multicenter biomarker study. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-026-04415-x

Chicago Style (17th ed.) Citation

S, Nakai, et al. "NY-ESO-1 and PD-L1 as Biomarkers Associated with Nivolumab Response and Outcome in Unresectable or Recurrent Esophageal Squamous Cell Carcinoma: A Multicenter Biomarker Study." Cancer Immunology, Immunotherapy : CII 2026. https://doi.org/10.1007/s00262-026-04415-x.

MLA (9th ed.) Citation

S, Nakai, et al. "NY-ESO-1 and PD-L1 as Biomarkers Associated with Nivolumab Response and Outcome in Unresectable or Recurrent Esophageal Squamous Cell Carcinoma: A Multicenter Biomarker Study." Cancer Immunology, Immunotherapy : CII, 2026, https://doi.org/10.1007/s00262-026-04415-x.